drugset / Trial / NCT00162201

An Exploratory Study of Changes in Synovial Immune Responses Following BMS-188667 Therapy in Subjects With Active Rheumatoid Arthritis on Background DMARDs Who Have Failed Anti-TNF Therapy

NCT00162201

Phase 1 Completed 16 enrolled Bristol-Myers Squibb
Non-randomizedSingle-groupOpen-labelTreatment

Summary

Study to assess changes in synovial tissue before and after treatment with Abatacept in subjects with RA who remained on their background disease modifying anti-arthritis medications but who have failed previous therapy with anti-TNF (tumor necrosing factor)blocking agents.

Timeline

Start
2003-10
Primary completion
2005-04
Completion
2005-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Abatacept Other / unclassified 500 mg Intravenous
Subject Abatacept Other / unclassified 750 mg Intravenous
Subject Abatacept Other / unclassified 1000 mg Intravenous

Indications